Human Vaccines and Immunotherapeutics

eISSN: 2164-554XpISSN: 2164-5515
JournalOpen Access

Check your submission readiness

Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.

Aims and Scope

Human Vaccines & Immunotherapeutics is a monthly peer-reviewed medical journal covering research into vaccines and immunotherapeutics in humans. It was established in 2005 as Human Vaccines, and obtained its current name in 2012. It is published by Taylor & Francis and the editor-in-chief is Ronald Ellis (FutuRx). According to the Journal Citation Reports, the journal had a 2013 impact factor of 3.643. Less

Key Metrics

CiteScore
5.5
H-Index
80
Impact Factor
< 5
Scite Index
0.83 5-Year SI
SJR
Q1Immunology
SNIP
1.36
Time to Publish
time-to-publish View Chart
4  Mo

Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
  • Publisher
    TAYLOR & FRANCIS INC
  • Language
    English
  • Frequency
    Monthly
  • Article Processing Charges
    EUR 2895 | GBP 2495 | USD 3175
  • Publication Time
    11
  • Editorial Review Process
    Anonymous peer review
General Details
  • Language
    English
  • Society/Institute/Sponsor
    International Society for Vaccines (ISV)
  • Frequency
    Monthly
  • Publication Start Year
    2012
  • Publisher URL
  • Website URL
Publication Details
Editorial Review Detail
Information for authors
View less
Time to Publish
Time to publish distribution
Articles published in year 2022
Time to publish index
Months% Papers published
0-3 31%
4-6 61%
7-9 6%
>9 2%

Topics Covered

Clinical trial
Human papillomavirus
Immunization
Influenza vaccine
Polysaccharide
Streptococcus pneumoniae
Immunotherapy
Social media
Performance improvement
Measles
Randomized controlled trial
Burden of disease
Rotavirus
Public health
Confidence interval
Hepatitis B
Seroconversion
Virus
Antigen
Conjugate vaccine

Recently Published Papers

Year-wise Publication

FAQs

Since when has Human Vaccines and Immunotherapeutics been publishing? Faqs

The Human Vaccines and Immunotherapeutics has been publishing since 2012 till date.

How frequently is the Human Vaccines and Immunotherapeutics published? Faqs

Human Vaccines and Immunotherapeutics is published Monthly.

What is the H-index. SNIP score, Citescore and SJR of Human Vaccines and Immunotherapeutics? Faqs

Human Vaccines and Immunotherapeutics has a H-index score of 80, Citescore of 5.5, SNIP score of 1.36, & SJR of Q1

Who is the publisher of Human Vaccines and Immunotherapeutics? Faqs

The publisher of Human Vaccines and Immunotherapeutics is TAYLOR & FRANCIS INC.

Where can I find a journal's aims and scope of Human Vaccines and Immunotherapeutics? Faqs

For the Human Vaccines and Immunotherapeutics's Aims and Scope, please refer to the section above on the page.

How can I view the journal metrics of Human Vaccines and Immunotherapeutics on editage? Faqs

For the Human Vaccines and Immunotherapeutics metrics, please refer to the section above on the page.

What is the eISSN and pISSN number of Human Vaccines and Immunotherapeutics? Faqs

The eISSN number is 2164-554X and pISSN number is 2164-5515 for Human Vaccines and Immunotherapeutics.

What is the focus of this journal? Faqs

The journal covers a wide range of topics inlcuding Clinical trial, Human papillomavirus, Immunization, Influenza vaccine, Polysaccharide, Streptococcus pneumoniae, Immunotherapy, Social media, Performance improvement, Measles, Randomized controlled trial, Burden of disease, Rotavirus, Public health, Confidence interval, Hepatitis B, Seroconversion, Virus, Antigen, Conjugate vaccine.

Why is it important to find the right journal for my research? Faqs

Choosing the right journal ensures that your research reaches the most relevant audience, thereby maximizing its scholarly impact and contribution to the field.

Can the choice of journal affect my academic career? Faqs

Absolutely. Publishing in reputable journals can enhance your academic profile, making you more competitive for grants, tenure, and other professional opportunities.

Is it advisable to target high-impact journals only? Faqs

While high-impact journals offer greater visibility, they are often highly competitive. It's essential to balance the journal's impact factor with the likelihood of your work being accepted.